Acadia Pharmaceuticals price target lowered to $15 from $17 at Mizuho

Mizuho analyst Uy Ear lowered the firm’s price target on Acadia Pharmaceuticals to $15 from $17 and keeps a Neutral rating on the shares. The analyst reduced sales forecasts for Nuplazid ahead of the company’s expected late-February 2023 guidance. He beli;eves his prior Nuplazid sales estimates, particularly for 2023, were optimistic given the ongoing challenges in the Parkinson’s disease market and the Inflation Reduction Act price increase restriction.